Association Between Maternal Obesity and Cesarean Delivery Complications

Zaheera Saadia1

  • 1Obstetrics and Gynecology, Qassim University College of Medicine, Buraidah, SAU.

Cureus
|April 8, 2020
PubMed

Background Several studies suggest that maternal obesity might be associated with intraoperative and postoperative complications of cesarean delivery. However, these results are not validated in the Pakistani population. Aim We aimed to assess the association between maternal obesity and intraoperative and postoperative complications of cesarean delivery. Methods We performed a retrospective observational study recording the prevalence of intraoperative and postoperative complications in women undergoing cesarean delivery. For all consecutive cesarean deliveries in Fehmida Sarfaraz hospital, Sialkot, Pakistan, we recorded the data of the maternal age, weight, body mass index (BMI), gestational age at delivery, intraoperative and postoperative complications, and the adverse pregnancy outcomes. We used the chi-square test, Spearman correlation, and linear regression to test the relationship between the study variables. Results We included 245 women in this study (non-obese group: n = 83; obese group: n = 162). BMI positively correlated with the incidence of deep venous thrombosis (DVT; r = 0.249), endometritis (r = 0.148), pyrexia (r=0.139), and wound infections (r = 0.155). Also, BMI could significantly predict DVT (Beta coefficient 2.886, P = 0.003), hospital stay (Beta coefficient 0.801, P = 0.001), pyrexia (Beta coefficient 0.819, P = 0.003), and wound infection (Beta coefficient 0.449, P = 0.049). Conclusion Our data suggest that BMI was significantly correlated with several cesarean section (CS) delivery complications. Obese women undergoing CS delivery are at higher risk of several CS delivery complications. Also, they had a longer hospital stay and higher birth weight for their neonates compared with non-obese women. Future multicentre studies are needed in our population to determine the magnitude of risk across different BMI subgroups.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.9K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
184
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
163
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
116